Metastasis-related long non-coding RNAs AL359220.1, SH3BP5-AS1 and ZF-AS1 are significant for prognostic assessment of lung adenocarcinoma.
long non-coding RNA
lung adenocarcinoma
metastasis
risk model
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
10 08 2023
10 08 2023
Historique:
received:
14
03
2023
accepted:
19
06
2023
medline:
22
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
Metastasis of lung adenocarcinoma (LUAD) severely worsens prognosis. Genetic alteration in the tumor microenvironment (TME) is closely associated with metastasis and other malignant biological properties of LUAD. In this study, we establish a metastasis-related risk model to accurately predict LUAD prognosis. RNA-sequencing profiles and clinical data of LUAD patients including 503 tumor tissues and 54 adjacent normal tissues were collected in TCGA database. Additionally, the paired specimens from 156 LUAD patients were obtained in a single center. The metastatic relevance and clinical significance of metastasis-related long non-coding RNA (MRLNRs) was validated by series of Six MRLNRs were significantly correlated to prognoses of LUAD patients, of which AL359220.1, SH3BP5-AS1 and ZF-AS1 were further used to establish a metastasis-related risk scoring model (MRRS) due to the close associations with overall survival of LUAD patients. According to the MRRS, patients with higher scores in the high-risk group obtained poorer prognoses and survival outcomes. ZFAS1 expressed highly in tumor tissues and showed the inverse results compared to SH3BP5-AS1 and AL359220.1. In addition, the high expression of ZFAS1 was prominently correlated to the more advanced T-stage and distant metastasis. The reduction of ZFAS1 induced by siRNAs dramatically diminished the migration and invasion abilities of LUAD cells. In the present research, we elucidate the metastatic relevance and clinical significance of AL359220.1, SH3BP5-AS1 and ZF-AS1 in LUAD. Moreover, MRRS provide a promising assessing model for clinical decision making and prognosis of LUAD.
Sections du résumé
BACKGROUND
Metastasis of lung adenocarcinoma (LUAD) severely worsens prognosis. Genetic alteration in the tumor microenvironment (TME) is closely associated with metastasis and other malignant biological properties of LUAD. In this study, we establish a metastasis-related risk model to accurately predict LUAD prognosis.
METHODS
RNA-sequencing profiles and clinical data of LUAD patients including 503 tumor tissues and 54 adjacent normal tissues were collected in TCGA database. Additionally, the paired specimens from 156 LUAD patients were obtained in a single center. The metastatic relevance and clinical significance of metastasis-related long non-coding RNA (MRLNRs) was validated by series of
RESULTS
Six MRLNRs were significantly correlated to prognoses of LUAD patients, of which AL359220.1, SH3BP5-AS1 and ZF-AS1 were further used to establish a metastasis-related risk scoring model (MRRS) due to the close associations with overall survival of LUAD patients. According to the MRRS, patients with higher scores in the high-risk group obtained poorer prognoses and survival outcomes. ZFAS1 expressed highly in tumor tissues and showed the inverse results compared to SH3BP5-AS1 and AL359220.1. In addition, the high expression of ZFAS1 was prominently correlated to the more advanced T-stage and distant metastasis. The reduction of ZFAS1 induced by siRNAs dramatically diminished the migration and invasion abilities of LUAD cells.
CONCLUSIONS
In the present research, we elucidate the metastatic relevance and clinical significance of AL359220.1, SH3BP5-AS1 and ZF-AS1 in LUAD. Moreover, MRRS provide a promising assessing model for clinical decision making and prognosis of LUAD.
Identifiants
pubmed: 37566767
pii: 204923
doi: 10.18632/aging.204923
pmc: PMC10457074
doi:
Substances chimiques
RNA, Long Noncoding
0
MicroRNAs
0
SH3BP5 protein, human
0
Adaptor Proteins, Signal Transducing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7551-7564Références
Cell Death Dis. 2021 May 2;12(5):439
pubmed: 33935284
Biol Direct. 2022 Nov 17;17(1):33
pubmed: 36397058
Thorac Cancer. 2019 Aug;10(8):1702-1709
pubmed: 31268619
Clin Transl Med. 2021 Sep;11(9):e478
pubmed: 34586722
J Immunother Cancer. 2022 Jan;10(2):
pubmed: 35140113
Cell Death Dis. 2018 Apr 18;9(5):450
pubmed: 29670111
Clin Transl Med. 2023 Jan;13(1):e1129
pubmed: 36650118
Thorac Cancer. 2020 Aug;11(8):2178-2187
pubmed: 32515146
Adv Sci (Weinh). 2022 Dec;9(34):e2203786
pubmed: 36257825
Mol Cancer. 2020 Jan 15;19(1):9
pubmed: 31941509
Nat Genet. 2020 Apr;52(4):371-377
pubmed: 32203465
Oncogene. 2021 Jul;40(26):4413-4424
pubmed: 34108619
Bioengineered. 2022 May;13(5):13437-13451
pubmed: 36700469
Biomed Pharmacother. 2018 Oct;106:755-762
pubmed: 29990868
Bioengineered. 2022 Jan;13(1):1276-1287
pubmed: 34738865
J Thorac Oncol. 2021 Feb;16(2):237-249
pubmed: 33188911
J Exp Clin Cancer Res. 2019 Jan 25;38(1):35
pubmed: 30683132
Onco Targets Ther. 2018 Aug 14;11:4877-4891
pubmed: 30147339
Arch Bronconeumol. 2021 Oct;57(10):650
pubmed: 35699046
Adv Sci (Weinh). 2021 Nov;8(22):e2101999
pubmed: 34622577
Oncogene. 2021 Dec;40(50):6748-6758
pubmed: 34663877
Mol Med. 2023 Jan 5;29(1):1
pubmed: 36604626
Cancer Lett. 2022 Feb 1;526:205-216
pubmed: 34838826
Adv Sci (Weinh). 2020 Mar 14;7(9):1903741
pubmed: 32382487
Adv Sci (Weinh). 2023 Mar;10(7):e2205262
pubmed: 36709476
Oncoimmunology. 2021 Sep 11;10(1):1959977
pubmed: 34527427
BMC Cancer. 2023 Jan 23;23(1):76
pubmed: 36690975
Cell. 2020 Jul 9;182(1):245-261.e17
pubmed: 32649877
Cancer Lett. 2020 Jun 1;479:31-41
pubmed: 32201203